Contract facts
UnrestrictedNo full NAICS 334516 intel page yet. Browse NAICS intelligence
The Purpose of This Acquisition Is to Enhance the Shared Research Capabilities of the National Cancer Institute (NCI),… is a federal Unrestricted award for Ibc Acq Svcs Directorate (00004) held by Element Biosciences, Inc. Estimated value $315K ($315K obligated). Current period of performance ends Sep 22, 2027. Last award drew 1 bidder. Place of performance: SAN DIEGO CA. Related solicitation 140D0426Q0826.
The purpose of this acquisition is to enhance the shared research capabilities of the national cancer institute (nci), center for cancer research (ccr), by acquiring an element biosciences aviti24 sequencing system for joint operation by the ccr geno
Recompete timing
PublicCurrent PoP ends Sep 22, 2027 (340 days remaining). Agencies typically plan 12–18 months ahead — at 11.2 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on 140D0426P0333? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordElement Biosciences, Inc — $1.5M obligated across 11 awards (firm-wide, all agencies) · lead buyer Department of Agriculture (USDA).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 140D0426P0333?
140D0426P0333 (NCI purpose this acquisition is) is a Ibc Acq Svcs Directorate (00004) award with a potential value of $315K, currently held by Element Biosciences, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 140D04-26-P-0333?
140D04-26-P-0333 is the dashed form of PIID 140D0426P0333 (NCI purpose this acquisition is), held by Element Biosciences, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 140D0426P0333?
Ibc Acq Svcs Directorate (00004) awarded 140D0426P0333 to Element Biosciences, Inc (potential $315K).
Who is the incumbent on 140D0426P0333?
Element Biosciences, Inc is the incumbent with $1.5M across 11 related awards in SCOUT’s public footprint. The current period of performance ends Sep 22, 2027.
When does Element Biosciences, Inc’s 140D0426P0333 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 22, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 140D0426P0333? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.